Clinical Trial Update: Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tripletrumab plus SOX as first-line treatment for gastric cancer and gastroesophageal junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• Teggio
• Tripletrumab

Snippet

Sponsor: RenJi Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN